Tennessee Senate Bill SB0152

Tennessee 2025-2026 Regular Session

• Introduced: 1/15/25
• Engrossed: 3/31/25

Caption

AN ACT to amend Tennessee Code Annotated, Title 53; Title 63 and Title 68, relative to stem cell treatment.

Impact

This legislation could significantly alter the landscape of healthcare related to stem cell treatments in Tennessee. It provides a framework for patients to access potentially life-altering therapies that are still in the clinical trial phase. However, it emphasizes the necessity for informed consent and the physician's recommendation. This could prompt more physicians to engage with and endorse investigational therapies, impacting patient treatment methodologies across the state.

Summary

Senate Bill 152, also known as the Stem Cell Treatment Bill, aims to amend the Tennessee Code Annotated to facilitate the use of investigational stem cell treatments for patients suffering from severe chronic diseases and terminal illnesses. The bill delineates the conditions under which patients can access these treatments, primarily focusing on those whose conditions have not been alleviated by existing FDA-approved options. Key to this process is the involvement of the patient's treating physician, who must ascertain that investigational treatments are the best available option for the patient.

Sentiment

The sentiment surrounding SB 152 appears largely positive among sponsor legislators and proponents of medical innovation, who argue that it expands patient access to potentially beneficial treatments that are currently unavailable through conventional means. However, there are concerns among some healthcare advocates regarding the ethical implications of using unapproved therapies, particularly regarding the adequacy of patient protections and the potential for exploitation in vulnerable populations.

Contention

Notable points of contention involve the balance between patient autonomy and the ethical responsibilities of healthcare providers. Critics may worry that the bill could lead to situations where patients opt for experimental treatments without fully understanding the risks, particularly in cases of terminal illness. Additionally, the bill's provisions against governmental interference could raise discussions about regulatory oversight and the ethical duties of healthcare practitioners in recommending such treatments.